Related Experiment Video
Updated: Nov 4, 2025
09:59
Application of AlDeSense to Stratify Ovarian Cancer Cells Based on Aldehyde Dehydrogenase 1A1 Activity
Published on: March 31, 2023
1.2K
Decrease of ABCB1 protein expression and increase of G1 phase arrest induced by oleanolic acid in human
Didi Wang1, Jincai Wang2, Juan Zhang2
1Key Laboratory of Microecology-immune Regulatory Network and Related Diseases, School of Basic Medicine, Jiamusi University, Jiamusi, Heilongjiang 154000, P.R. China.
Experimental and Therapeutic Medicine
|May 31, 2021
Summary
Oleanolic acid (OA) enhances sensitivity in multidrug-resistant cancer cells by reducing ABCB1 expression and inducing G1 phase arrest. This natural compound shows potential for cancer therapy by overcoming drug resistance.
Area of Science:
- Natural Product Chemistry
- Cancer Biology
- Pharmacology
Background:
- Oleanolic acid (OA) is a plant-derived compound with diverse biological activities.
- The precise mechanism of OA action in human tumor cells, particularly in overcoming drug resistance, is not fully understood.
- Caveolin-1 overexpression was previously linked to OA sensitivity in leukemia cells.
Purpose of the Study:
- To investigate the effects of Oleanolic acid (OA) on drug-resistant human breast cancer (MCF-7/DOX) and leukemia (HL-60/HAR) cell lines.
- To evaluate the role of caveolin-1 in OA sensitivity in resistant breast cancer cells.
- To determine the impact of OA on cell cycle progression, apoptosis, and drug resistance mechanisms, specifically ABCB1 expression.
Main Methods:
- Cell viability assays (CCK-8) to assess drug sensitivity.
- Western blotting to measure protein expression levels.
- Flow cytometry for cell cycle analysis and apoptosis assays (Annexin V/PI staining).
- Rhodamine 123 accumulation assay to evaluate ABCB1 substrate activity.
Main Results:
- Oleanolic acid (OA) demonstrated increased sensitivity in harringtonine-resistant HL-60/HAR cells compared to parental HL-60 cells.
- Doxorubicin-resistant MCF-7/DOX cells showed similar OA susceptibility regardless of caveolin-1 expression levels.
- OA treatment induced G1 phase arrest in both resistant cell lines and promoted apoptosis, although not through classical caspase-3/PARP-1 cleavage.
- OA treatment decreased ATP-binding cassette subfamily B member 1 (ABCB1) protein expression in a concentration-dependent manner in resistant cells and was not an ABCB1 substrate.
Conclusions:
- Oleanolic acid (OA) exhibits potential in combating multidrug resistance in cancer cells.
- OA's efficacy may stem from its ability to downregulate ABCB1 protein expression and induce G1 cell cycle arrest.
- Further research into OA as a therapeutic agent for resistant cancers is warranted.
Keywords:
ATP-binding cassette subfamily B member 1caveolin-1cell cyclemultidrug resistance in tumoroleanolic acidMore Related Videos
Related Concept Videos
02:56Treatment Resistant Cancers
3.5K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.5K
02:34Inhibition of Cdk Activity
5.1K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K